ObjectiveTo investigate the clinical effect and safety of ultra-early anticoagulation in patients with acute high-risk pulmonary embolism. MethodsThe retrospective study method was conducted, 60 patients with acute high-risk pulmonary embolism who were diagnosed and treated in Guangxi Yulin Orthopedic Hospital of Integrated Traditional Chinese and Western Medicine from September 2018 to November 2021 were selected as the observation group, and 60 patients with acute high-risk pulmonary embolism who were treated in other tertiary general hospitals in Yulin City during the same period were selected as the control group. The patients in the control group received anticoagulation combined with thrombolysis therapy after being diagnosed with acute high-risk pulmonary embolism, while the patients in the observation group received ultra-early multi-target anticoagulation therapy immediately after being suspected of acute high-risk pulmonary embolism, and continued to receive anticoagulation combined with thrombolysis therapy after being diagnosed. The levels of arterial partial pressure of oxygen (PaO2), arterial partial pressure of carbon dioxide (PaCO2), arterial oxygen saturation (SaO2), plasma D-dimer level, and plasma activated partial thromboplastin time (APTT) level before and after the treatment, as well as clinical efficacy and incidence of adverse reactions, were compared between the two groups. ResultsBefore the treatment, there was no significant difference in PaO2, PaCO2 or SaO2 between the two groups (all P＞0.05), and after the 24-hour treatment, the levels of PaO2 and SaO2 in the observation group were higher than those in the control group, while the level of PaCO2 was lower than that in the control group (all P＜0.05). Before the treatment, there was no statistically significant difference in the plasma D-dimer or APTT level between the two groups (all P＞0.05), and after the 2-week treatment, the plasma levels of D-dimer and APTT in the observation group were lower than those in the control group (all P＜0.05). After the 2-week treatment, the total therapeutic effective rate of patients in the observation group was 91.67%, which was higher than that in the control group (76.67%) (P＜0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups during the hospitalization (P＞0.05). ConclusionUltra-early anticoagulation therapy can improve the respiratory function, coagulation and fibrinolytic system function of patients with acute high-risk pulmonary embolism, and improve the therapeutic effect, which has high safety value.

无